Unraveling the Biologic and Clinical Complexities of HER2

Park, John W.; Neve, Richard M.; Szollosi, Janos; Benz, Christopher C.
December 2008
Clinical Cancer Update;Dec2008, Vol. 2 Issue 1, p18
Academic Journal
It has been over 20 years since the discovery of the human epidermal growth factor receptor 2 (HER2), a tyrosine kinase receptor that is a potent oncoprotein in breast and other cancers and has become an opportune target for therapy. HER2 plays a critical role in normal development, forming homodimers or heterodimers with other HER family members and triggering downstream signaling cascades controlling proliferation, cell survival, and apoptosis. However, amplification of the HER2 gene in cancer cells results in overexpression of HER2 receptors on the cell surface, leading to excessive and dysregulated signaling. HER2-driven signaling also upregulates transcription factors that act on the HER2 promoter, increasing its expression. In breast cancer, HER2 is gene amplified in 20%-25% of primary tumors and is associated with a more aggressive phenotype and poorer prognosis. The key role HER2 plays in tumorigenesis makes it an ideal target for therapy. Trastuzumab, a monoclonal antibody against HER2, inhibits downstream signaling and has proven to be effective against HER2-overexpressing metastatic breast cancer both as a single agent and in combination with chemotherapy. Seminal clinical trial data also show that the use of adjuvant trastuzumab in combination with chemotherapy or as a single agent after chemotherapy significantly increases disease-free and overall survival. Lapatinib, a dual tyrosine kinase inhibitor against HER1 and HER2, has been approved in combination with capecitabine for HER2-overexpressing advanced or metastatic breast cancer, which has progressed following previous anthracycline, taxane, and trastuzumab therapy. Other HER2-targeting strategies are also under active investigation.


Related Articles

  • Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer. Schroeder, Richard L.; Stevens, Cheryl L.; Sridhar, Jayalakshmi // Molecules;Sep2014, Vol. 19 Issue 9, p15196 

    The human epidermal growth factor receptor 2 (HER2) is a member of the erbB class of tyrosine kinase receptors. These proteins are normally expressed at the surface of healthy cells and play critical roles in the signal transduction cascade in a myriad of biochemical pathways responsible for...

  • Neratinib, an irreversible erbB receptor tyrosine Kinase inhibitor, in patients with advanced erbB2-positive breast cancer. Sharma, Anand; Jayanth, Akali // Advances in Breast Cancer;Mar2010, Vol. 7 Issue 1, p21 

    In this article, the authors discuss the findings of a study concerning the effectiveness of neratinib, a tyrosine-kinase inhibitor of human epidermal growth factor-like 2 (HER-2), in the treatment of advanced HER2-positive breast cancer. They suggest that a larger phase III clinical trial is...

  • Challenges in Developing New Biomarkers for Breast Cancer. Batsis, Charalabos; Makris, John // World Journal of Surgery;Nov2010, Vol. 34 Issue 11, p2790 

    The article presents a study on the challenges in the development of biomarkers for breast cancer. The study shows modest improvement in estrogenreceptor (ER), human epidermal growth factor receptor 2 (HER2), and progesterone-receptor (PR). The positivity of HER2 as an indicator of early relapse...

  • A Novel Method of Reporting c-erbB-2 Overexpression: Correlation with Grade But Not with Other Prognostic Parameters in Breast Cancer. Samur, Mustafa; Karaveli, Seyda; Bozcuk, Hakan; Pestereli, Elif; Özdogan, Mustafa; Yildiz, Mustafa; Artac, Mehmet; Savas, Burhan // Turkish Journal of Medical Sciences;2003, Vol. 33 Issue 6, p363 

    Overexpression of erbB-2 protein is a marker of clinically aggressive behavior in breast cancer patients. In general erbB- 2 status is reported on a scale from negative to 3+, depending on staining intensity, if more than 10% of the tumor cells are stained. However, the original definition does...

  • Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome. Umemura, S.; Shirane, M.; Takekoshi, S.; Kusakabe, T.; Itoh, J.; Egashira, N.; Tokuda, Y.; Mori, K.; Osamura, Y. R. // British Journal of Cancer;3/10/2009, Vol. 100 Issue 5, p764 

    The purpose of the present study is to identify genes that contribute to cell proliferation or differentiation of breast cancers independent of signalling through the oestrogen receptor (ER) or human epidermal growth factor receptor 2 (HER2). An oligonucleotide microarray assayed 40 tumour...

  • Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Hiscox, Stephen // Advances in Oncology;2010, Vol. 5 Issue 2, p19 

    In this article, the author discusses the implication of ErgB2 tyrosine kinase inhibitors in gene amplification and protein overexpression for breast cancers. It evaluates the development of lapatinib, the dual tyrosine-kinase inhibitor of epidermal growth factor receptor (EGFR) and HER2 as an...

  • Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. Pradeep, C-R; Zeisel, A; Köstler, W J; Lauriola, M; Jacob-Hirsch, J; Haibe-Kains, B; Amariglio, N; Ben-Chetrit, N; Emde, A; Solomonov, I; Neufeld, G; Piccart, M; Sagi, I; Sotiriou, C; Rechavi, G; Domany, E; Desmedt, C; Yarden, Y // Oncogene;8/2/2012, Vol. 31 Issue 31, p3569 

    The HER2/neu oncogene encodes a receptor-like tyrosine kinase whose overexpression in breast cancer predicts poor prognosis and resistance to conventional therapies. However, the mechanisms underlying aggressiveness of HER2 (human epidermal growth factor receptor 2)-overexpressing tumors remain...

  • High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis. Al Moustafa, Ala-Eddin; Kassab, Amal; Darnel, Andrew; Yasmeen, Amber // Current Pharmaceutical Design;Aug2008, Vol. 14 Issue 22, p2159 

    Human papillomaviruses (HPVs) are a group of host-specific DNA viruses, with more than 120 different types identified to date. HPVs are classified as high- or low-risk (HR or LR) depending on their potential to induce cancer. Persistent infections with HR types of HPVs present a major risk...

  • Confirmation of a low HER2 positivity rate of breast carcinomas--limitations of immunohistochemistry and in situ hybridization. Vogel, Ulrich F. // Diagnostic Pathology;2010, Vol. 5, p50 

    Background: Accurate assessment of the human epidermal growth factor receptor 2 (HER2) of invasive breast cancer is essential to treatment decisions since the advent of targeted therapy with the humanized monoclonal antibody trastuzumab and the dual tyrosine kinase inhibitor lapatinib. In the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics